JUNS (Jupiter Neurosciences, Inc.) Market Value to Book Value Ratio
Jupiter Neurosciences Inc (JUNS) is developing unique treatment methods for brain pathologies, aiming for dominance in the Alzheimer's therapy segment. Business stability is guaranteed by a cohesive staff of leading neurologists whose dedication precludes personnel loss. The asset value tracked on the chart is -4.80, with profits expected to be generated through the implementation of resveratrol-based innovations to combat epilepsy and Parkinson's disease.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_JUNS_-_Jupiter-Neurosciences-Inc_-_Capitalization-to-Book-Value-Ratio "JUNS Jupiter Neurosciences Market Capitalization to Book Value Ratio (12/04/2024 - 10/28/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Jupiter Neurosciences, Inc. (JUNS)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Fundamental valuation:JUNS - Jupiter Neurosciences
This ratio compares the market value of the business to its net assets, determining the premium for future growth. For Jupiter Neurosciences Inc (JUNS), the company's valuation history via the P/B ratio reflects market expectations regarding the bioavailability of the JNS101 drug. High values indicate that investors are betting on the therapeutic success of resveratrol. Analyzing the price action allows for the identification of an overbought asset. Ignoring these peaks risks significant losses during a correction.
Main competitors
Biogen Inc. - Market Value to Book Value Ratio|NBIX (neurocrine.com) - Market Capitalization to Book Value|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|BHVN (Biohaven Corp) - Market-to-Book Ratio|Amylyx Pharmaceuticals (AMLX) - Market Value to Book Value Ratio|Market Cap to Book Value Multiple trevitherapeutics.com (TRVI)|Market Cap to Net Assets Ratio PRAX|Market Capitalization to Book Value Ratio AVXL (Anavex)|CeriBell Corp (CBLL) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Prothena PRTA|Market Capitalization to Book Value Ratio ALEC (Alector Therapeutics)|annexonbio.com (ANNX) - Market Capitalization to Book Value|OMER - Market Cap to Net Assets Ratio|Neurogene Inc (NGNE) - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio ACIU (AC Immune Corp)|Market-to-Book Ratio VYGR|Neumora Therapeutics (NMRA) - Market Value to Book Value Ratio|Market Value to Book Value scilexholding.com SCLX|Market Cap to Net Assets Ratio Tevogen Bio|Alpha Cognition Inc - Market Value to Book Value|Cognition Therapeutics, Inc. (CGTX) - Market Value to Book Value Ratio|IKT - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio SAVA|Market-to-Book Ratio Assertio|COYA (Coya Therapeutics Inc) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio VTGN|Ovid Therapeutics Inc. (OVID) - Market Value to Book Value Ratio|Market Value to Book Value ABOS (Acumen Pharmaceuticals, Inc)|CRVO: Market Value to Book Value Ratio|Alterity Therapeutics Ltd. - Market-to-Book Ratio|Market Value to Book Value Ratio CLNN (Clene Nanomedicine)|PEPG - Market Capitalization to Book Value|RLMD (Relmada) - Market Capitalization to Book Value Ratio|Annovis Bio Corporation (ANVS) - Market Cap to Net Assets Ratio|GRCE: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value fireflyneuro.com|Klotho Neurosciences Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio NRSN (neurosense-tx.com)|RVPH - Market Value to Book Value Ratio|Capitalization to Book Value Ratio MetaVia Inc. MTVA|NRXS: Market Capitalization to Book Value Ratio|HSDT - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio PASG|NEUP (Neuphoria Therapeutics) - Market-to-Book Ratio|NERV: Market Value to Book Value Ratio|Market Capitalization to Book Value Athira Pharma Corp (ATHA)|Addex Therapeutics (ADXN) - Market Cap to Net Assets Ratio|Market Value to Book Value alzamend.com (ALZN)|Market Capitalization to Book Value Ratio CYCN|Protagenic Therapeutics Inc. - Market Capitalization to Book Value|Pasithea (KTTA) - Market Value to Book Value Ratio|CRGT - Capitalization to Book Value Ratio|ATXI (Avenue Therapeutics) - Market Capitalization to Book Value Ratio|BCLI (brainstorm-cell.com) - Market Cap to Net Assets Ratio|Cara Therapeutics (CARA) - Market Value to Book Value Ratio|Market Cap to Book Value Multiple Chromocell Therapeutics Corp (CHRO)|Market Cap to Net Assets Ratio ELYM|Market Capitalization to Book Value Ratio ITCI (intracellulartherapies.com)|LBPH - Market Value to Book Value Ratio|marinuspharma.com - Capitalization to Book Value Ratio|Market Value to Book Value Ratio NKGN (NKGen Biotech)|NRBO: Market Capitalization to Book Value|Market Value to Book Value Ratio Sage Therapeutics, Inc|Synaptogenix, Inc (SNPX) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio TRVN (Trevena, Inc.)|Market-to-Book Ratio Vigil Neuro (VIGL)|Market Cap to Net Assets Ratio WENA|Market Capitalization to Book Value Ratio CERE (Cerevel Therapeutics Inc)